Welcome to the latest of our Eberhard F. Mammen award announcements. As noted in previous
editorials ([Table 1]), Thieme Medical and Scientific Publisher, the publisher of Seminars in Thrombosis and Hemostasis (STH), has created the “Eberhard F. Mammen Excellence in Thrombosis and Hemostasis Awards” in honor of Eberhard F. Mammen ([Fig. 1]) in recognition of his contribution to this field and to the journal that he both
founded and steered for over three decades. These awards began in 2009, under two
categories, “Most Popular Article Awards” and “Young Investigator Awards.” Accordingly,
2021 represents in excess of 10 years of award presentations ([Table 1]). Current details and conditions of the award can be summarized as follows:
-
Most popular article awards: will be awarded to the authors of the most popular articles
published in STH. The awards are determined by the Editor in Chief on the basis of
user statistics from Thieme e-Journals from the preceding 2 years. Prefaces, Errata,
Letters to the Editor, Editorials, Commentaries, and previous award-winning articles
are excluded from further consideration of these awards which currently comprise two
categories: one for “Open Access” articles and another for a “General Category.” There
are two major cash prizes of U.S. $1,000 for each category. In addition, winners of
the “General Category” awards are granted “Open Access” status for these articles
thereafter.
-
Young investigator awards: the best presentation or meeting abstract by a young investigator
as presented or delivered to an international or large regional meeting on a topic
related to the fields of thrombosis and hemostasis, and whose subject matter is determined
to be in the spirit of Dr. Mammen. Up to six cash prizes of U.S. $1,000 in any year.
There are some additional considerations and conditions for the award, and awardees
are expected to prepare a review or other paper related to the topic of their presentation
(or as otherwise agreed) for publication in STH. In general, previous award winners
are excluded from a second award to enable more individuals to be recognized. After
nominations are received, the awardees are selected by a vote of the Senior Editors
of STH. Any potential conflicts of interest are managed by first identifying these,
and then excluding those with potential conflicts from voting. Finally, given the
current COVID-19 (novel coronavirus disease 2019) pandemic, many international congresses
have become virtual meetings, and accordingly, virtual meeting presentations can also
be considered for the award.
Table 1
Previous editorials related to Eberhard F. Mammen award announcements
|
1. Favaloro EJ. Welcome to a special issue of seminars in thrombosis and hemostasis—the
closing issue for 2008. Semin Thromb Hemost 2008;34:693–696
2. Favaloro EJ. A tribute to Eberhard F. Mammen, M.D. (1930-2008). Semin Thromb Hemost
2008;34(8):703–707
3. Favaloro EJ. Welcome to the first issue of Seminars in Thrombosis and Hemostasis
for 2009. Semin Thromb Hemost 2009;35:1–2
4. Favaloro EJ. Winners of the inaugural Eberhard F. Mammen award for most popular
article. Semin Thromb Hemost 2009;35:587–590
5. Favaloro EJ. Editorial. 2009 Eberhard F. Mammen young investigator award winners.
Semin Thromb Hemost 2010;36:469–470
6. Favaloro EJ. Winners of the 2010 Eberhard F. Mammen award for most popular article
during 2008-2009. Semin Thromb Hemost 2010;36(7):685–692
7. Favaloro EJ. 2011 Eberhard F. Mammen award announcements. Semin Thromb Hemost 2011;37(5):431–439
8. Favaloro EJ. 2012 Eberhard F. Mammen award announcements. Semin Thromb Hemost 2012;38:425–432
9. Favaloro EJ. Eberhard F. Mammen award announcements. Semin Thromb Hemost 2013;39:567–574
10. Favaloro EJ. 2014 Eberhard F. Mammen award announcements: part I—most popular
articles. Semin Thromb Hemost 2014;40(4):407–412
11. Favaloro EJ. 2014 Eberhard F. Mammen award announcements: part II—Young Investigator
Awards. Semin Thromb Hemost 2014;40(7):718–723
12. Favaloro EJ. 2015 Eberhard F. Mammen award announcements: part I—most popular
articles. Semin Thromb Hemost 2015;41(7):673–679
13. Favaloro EJ. 2015 Eberhard F. Mammen award announcements: part II—young investigator
awards. Semin Thromb Hemost 2015;41(8):809–815
14. Favaloro EJ. 2016 Eberhard F. Mammen award announcements: part I—most popular
articles. Semin Thromb Hemost 2016;42(4):325–330
15. Favaloro EJ. 2016 Eberhard F. Mammen Award announcements: part II—young investigator
awards. Semin Thromb Hemost 2017;43(3):235–241
16. Favaloro EJ. 2017 Eberhard F. Mammen award announcements: part I—most popular
articles. Semin Thromb Hemost 2017;43(4):357–363
17. Favaloro EJ. 2017 Eberhard F. Mammen award announcements: part II—young investigator
awards. Semin Thromb Hemost 2018;44(2):81–88
18. Favaloro EJ. 2018 Eberhard F. Mammen award announcements: part I—most popular
articles. Semin Thromb Hemost 2018;44(3):185–192
19. Favaloro EJ. 2018 Eberhard F. Mammen award announcements: part II—young investigator
awards. Semin Thromb Hemost 2019;45(2):123–129
20. Favaloro EJ. 2019 Eberhard F. Mammen award announcements: part I—most popular
articles. Semin Thromb Hemost 2019;45(3):215–224
21. Favaloro EJ. 2019 Eberhard F. Mammen award announcements: part II—young investigator
awards. Semin Thromb Hemost 2020;46(2):105–113
22. Favaloro EJ. 2020 Eberhard F. Mammen award announcements: part I—most popular
articles. Semin Thromb Hemost 2020;46(4):383–392
23. Favaloro EJ. 2020 Eberhard F. Mammen award announcements: part II—young investigator
awards. Semin Thromb Hemost 2021;46(3): 229–237
|
Fig. 1 Eberhard F. Mammen (1930–2008).
Further details of the awards and the award winners are posted online (
https://www.thieme-connect.com/products/ejournals/journal/10.1055/s-00000077
), and previous award winner announcements are also available in print ([Table 1]). This includes the recent announcement of the 2020 Young Investigator Awards.[1]
It is, therefore, with great pleasure that we would like to announce the latest winners
of the 2021 Eberhard F. Mammen awards for the most popular articles from STH for the
period of 2019 to 2020 inclusive.
2021 “Most Popular” Article Awards
As mentioned, the “Most Popular” awards are given to the authors of the most popular
articles published in STH as determined on the basis of user statistics from the publisher
of this journal and covering the preceding 2-year period. Thus, the 2021 “Most Popular”
awards are granted to the most popular papers from 2019 to 2020 inclusive. Previous
Eberhard F. Mammen award winning articles are listed in [Table 2]. These articles are currently freely available under an “Open Access” status and
no longer qualify for future awards, although many will continue to appear in the
most popular download statistics provided by the publisher. Indeed, as expected, many
of the previous award-winning articles appeared in the top 100 list (2019–2020 inclusive),
with most also ranking highly, and thus still proving popular with our readership.
Table 2
Previous most popular award-winning papers
|
Year
|
Awarded for
|
Position in 2021 top 100 list
|
|
2009
|
Jurk K, Kehrel BE. Platelets: physiology and biochemistry. Semin Thromb Hemost 2005;31(4):381–392
|
15
|
|
2009
|
Girolami B, Girolami A. Heparin-induced thrombocytopenia: a review. Semin Thromb Hemost
2006;32(8):803–809
|
NL
|
|
2010
|
Harenberg J, Wehling M. Current and future prospects for anticoagulant therapy: inhibitors
of factor Xa and factor IIa. Semin Thromb Hemost 2008;34(1):39–57
|
NL
|
|
2010
|
Prechel M, Walenga JM. The laboratory diagnosis and clinical management of patients
with heparin-induced thrombocytopenia: an update. Semin Thromb Hemost 2008;34(1):86–96
|
NL
|
|
2010
|
Fareed J, Hoppensteadt DA, Fareed D, et al. Survival of heparins, oral anticoagulants,
and aspirin after the year 2010. Semin Thromb Hemost 2008;34(1):58–73
|
NL
|
|
2011
|
Sobieraj-Teague M, O'Donnell M, Eikelboom J. New anticoagulants for atrial fibrillation.
Semin Thromb Hemost 2009;35(5):515–524
|
NL
|
|
2011
|
Mariani G, Bernardi F. Factor VII deficiency. Semin Thromb Hemost 2009;35(4):400–406
|
13
|
|
2012
|
Lippi G, Franchini M, Favaloro EJ, Targher G. Moderate red wine consumption and cardiovascular
disease risk: beyond the “French paradox”. Semin Thromb Hemost 2010;36(1):59–70
|
11
|
|
2012
|
Rak J. Microparticles in cancer. Semin Thromb Hemost 2010;36(8):888–906
|
45
|
|
2013
|
Fava C, Montagnana M, Favaloro EJ, Guidi GC, Lippi G. Obstructive sleep apnea syndrome
and cardiovascular diseases. Semin Thromb Hemost 2011;37(3):280–297
|
68
|
|
2013
|
Tufano A, Guida A, Di Minno MN, Prisco D, Cerbone AM, Di Minno G. Prevention of venous
thromboembolism in medical patients with thrombocytopenia or with platelet dysfunction:
a review of the literature. Semin Thromb Hemost 2011;37(3):267–274
|
28
|
|
2014
|
Salmela B, Joutsi-Korhonen L, Armstrong E, Lassila R. Active online assessment of
patients using new oral anticoagulants: bleeding risk, compliance, and coagulation
analysis. Semin Thromb Hemost 2012;38(1):23–30
|
NL
|
|
2014
|
Chapman K, Seldon M, Richards R. Thrombotic microangiopathies, thrombotic thrombocytopenic
purpura, and ADAMTS-13. Semin Thromb Hemost 2012;38(1):47–54
|
75
|
|
2014
|
Kenet G, Aronis S, Berkun Y, et al. Impact of persistent antiphospholipid antibodies
on risk of incident symptomatic thromboembolism in children: a systematic review and
meta-analysis. Semin Thromb Hemost 2011;37(7):802–809
|
22
|
|
2015
|
Tapson VF. Thrombolytic therapy for acute pulmonary embolism. Semin Thromb Hemost
2013;39(4):452–458
|
47
|
|
2015
|
George JN, Charania RS. Evaluation of patients with microangiopathic hemolytic anemia
and thrombocytopenia. Semin Thromb Hemost 2013;39(2):153–160
|
42
|
|
2015[a]
|
Hylek EM. Anticoagulation therapy for atrial fibrillation. Semin Thromb Hemost 2013;39(2):147–152
|
NL
|
|
2015[a]
|
Rojas-Hernandez CM, Garcia DA. The novel oral anticoagulants. Semin Thromb Hemost
2013;39(2):117–126
|
NL
|
|
2016
|
de Moerloose P, Casini A, Neerman-Arbez M. Congenital fibrinogen disorders: an update.
Semin Thromb Hemost 2013;39(6):585–595
|
9
|
|
2016
|
Sethi S, Fervenza FC. Pathology of renal diseases associated with dysfunction of the
alternative pathway of complement: C3 glomerulopathy and atypical hemolytic uremic
syndrome (aHUS). Semin Thromb Hemost 2014;40(4):416–421
|
49
|
|
2016[a]
|
Bates SM. D-dimer assays in diagnosis and management of thrombotic and bleeding disorders.
Semin Thromb Hemost 2012;38(7):673–682
|
52
|
|
2016[a]
|
Lippi G, Favaloro EJ, Meschi T, Mattiuzzi C, Borghi L, Cervellin G. E-cigarettes and
cardiovascular risk: beyond science and mysticism. Semin Thromb Hemost 2014;40(1):60–65
|
6
|
|
2017
|
Boonyawat K, Crowther MA. Venous thromboembolism prophylaxis in critically ill patients.
Semin Thromb Hemost 2015;41(1):68–74
|
19
|
|
2017
|
Levi M, Poll TV. Coagulation in patients with severe sepsis. Semin Thromb Hemost 2015;41(1):9–15
|
65
|
|
2017[a]
|
Moore GW. Recent guidelines and recommendations for laboratory detection of lupus
anticoagulants. Semin Thromb Hemost 2014;40(2):163–171
|
7
|
|
2017[a]
|
Warkentin TE. Heparin-induced thrombocytopenia in critically ill patients. Semin Thromb
Hemost 2015;41(1):49–60
|
55
|
|
2017[b]
|
Favaloro EJ, Lippi G. Laboratory testing in the era of direct or non-vitamin K antagonist
oral anticoagulants: a practical guide to measuring their activity and avoiding diagnostic
errors. Semin Thromb Hemost 2015;41(2):208–227
|
53
|
|
2018
|
Gremmel T, Frelinger AL III, Michelson AD. Platelet physiology. Semin Thromb Hemost
2016;42(3):191–204
|
1
|
|
2018
|
Mallett SV. Clinical utility of viscoelastic tests of coagulation (TEG/ROTEM) in patients
with liver disease and during liver transplantation. Semin Thromb Hemost 2015;41(5):527–537
|
35
|
|
2018[a]
|
Cuker A, Prak ET, Cines DB. Can immune thrombocytopenia be cured with medical therapy?
Semin Thromb Hemost 2015;41(4):395–404
|
59
|
|
2018[a]
|
Cuker A. Clinical and laboratory diagnosis of heparin-induced thrombocytopenia: an
integrated approach. Semin Thromb Hemost 2014;40(1):106–114
|
77
|
|
2019
|
Klil-Drori AJ, Tagalakis V. Direct oral anticoagulants in end-stage renal disease.
Semin Thromb Hemost 2018;44(4):353–363
|
16
|
|
2019
|
Kitchen S, Tiefenbacher S, Gosselin R. Factor activity assays for monitoring extended
half-life FVIII and factor IX replacement therapies. Semin Thromb Hemost 2017;43(3):331–337
|
37
|
|
2019[a]
|
Kell DB, Pretorius E. To what extent are the terminal stages of sepsis, septic shock,
systemic inflammatory response syndrome, and multiple organ dysfunction syndrome actually
driven by a prion/amyloid form of fibrin? Semin Thromb Hemost 2018;44(3):224–238
|
27
|
|
2019[a]
|
Chighizola CB, Raimondo MG, Meroni PL. Management of thrombotic antiphospholipid syndrome.
Semin Thromb Hemost 2018;44(5):419–426
|
41
|
|
2020
|
Kumar KR, Cowley MJ, Davis RL. Next-generation sequencing and emerging technologies.
Semin Thromb Hemost 2019;45(7):661–673
|
5
|
|
2020
|
Russo V, Attena E, Mazzone C, et al. Nonvitamin K antagonist oral anticoagulants use
in patients with atrial fibrillation and bioprosthetic heart valves/prior surgical
valve repair: a multicenter clinical practice experience. Semin Thromb Hemost 2018;44(4):364–369
|
60
|
|
2020[a]
|
Lippi G, Favaloro EJ, Sanchis-Gomar F. Sudden cardiac and noncardiac death in sports:
epidemiology, causes, pathogenesis, and prevention. Semin Thromb Hemost 2018;44(8):780–786
|
24
|
|
2020[a]
|
Schreiber K, Breen K, Cohen H, et al. HYdroxychloroquine to improve pregnancy outcome
in women with AnTIphospholipid Antibodies (HYPATIA) protocol: a multinational randomized
controlled trial of hydroxychloroquine versus placebo in addition to standard treatment
in pregnant women with antiphospholipid syndrome or antibodies. Semin Thromb Hemost
2017;43(6):562–571
|
23
|
Abbreviation: NL, not listed in top 100 listing.
a New open access category created in 2015.
b This paper qualified as a “Most Popular” award winner based on objective publisher
provided download data; however, as this paper was written by the journal Editor in
Chief, there was an obvious conflict of interest, and the award was officially declined.
This paper is listed here merely as a statement of record.
There is also an increasingly recognized trend to publish articles under an open-access
model, and these, therefore, have an “‘inequitable advantage” over other “non–open
access” articles in terms of potential for downloads or perceived popularity due to
their open accessibility. Accordingly, the publisher of STH established a separate
category of the “Most Popular” award for “Open Access” papers to supplement the original
and now alternate “General Category.” Thus, the most popular papers are now listed
in separate tables. [Table 3] lists the top 20 downloaded “Open Access” articles from STH (2019 and 2020 inclusive),
as eligible for the “Open Access” award.[2]
[3]
[4]
[5]
[6]
[7]
[8]
[9]
[10]
[11]
[12]
[13]
[14]
[15]
[16]
[17]
[18]
[19]
[20]
[21]
[Table 4] lists the top 25 downloaded non–open access articles from STH (2019 and 2020 inclusive),
as otherwise eligible for the “‘General Category” award.[22]
[23]
[24]
[25]
[26]
[27]
[28]
[29]
[30]
[31]
[32]
[33]
[34]
[35]
[36]
[37]
[38]
[39]
[40]
[41]
[42]
[43]
[44]
[45]
[46]
Table 3
Most popular papers—“Open Access” category[a]
|
Rank
|
Publication
|
|
1
|
Gosselin RC, Adcock D, Dorgalaleh A, et al. International Council for Standardization
in Haematology recommendations for hemostasis critical values, tests, and reporting.
Semin Thromb Hemost 2020;46(4):398–409
|
|
2
|
Gosselin RC, Marlar RA. Preanalytical variables in coagulation testing: setting the
stage for accurate results. Semin Thromb Hemost 2019;45(5):433–448
|
|
3
|
Page MJ, Pretorius E. A champion of host defense: a generic large-scale cause for
platelet dysfunction and depletion in infection. Semin Thromb Hemost 2020;46(3):302–319
|
|
4
|
Al-Samkari H, Kuter DJ. Immune thrombocytopenia in adults: modern approaches to diagnosis
and treatment. Semin Thromb Hemost 2020;46(3):275–288
|
|
5
|
Di Minno A, Ambrosino P, Calcaterra I, Di Minno MND. COVID-19 and venous thromboembolism:
a meta-analysis of literature studies. Semin Thromb Hemost 2020;46(7):763–771
|
|
6
|
Harenberg J, Schreiner R, Hetjens S, Weiss C. Detecting anti-IIa and anti-Xa direct
oral anticoagulant (DOAC) agents in urine using a DOAC dipstick. Semin Thromb Hemost
2019;45(3):275–284
|
|
7
|
Althaus K, Greinacher A. MYH9-related platelet disorders. Semin Thromb Hemost 2009;35(2):189–203
|
|
8
|
Lippi G, Danese E, Favaloro EJ. Harms and benefits of using aspirin for primary prevention
of cardiovascular disease: a narrative overview. Semin Thromb Hemost 2019;45(2):157–163
|
|
9
|
Lippi G, Salvagno GL, Gelati M, Poli G, Giavarina D, Favaloro EJ. Analytical assessment
of the new Roche Cobas t 711 fully automated coagulation analyzer. Semin Thromb Hemost
2019;45(3):308–314
|
|
10
|
Lindholm PF, Ramsey G, Kwaan HC. Passive immunity for coronavirus disease 2019: a
commentary on therapeutic aspects including convalescent plasma. Semin Thromb Hemost
2020;46(7):796–803
|
|
11
|
van der Vorm LN, Huskens D, Kicken CH, et al. Effects of repeated bouts of exercise
on the hemostatic system. Semin Thromb Hemost 2018;44(8):710–722
|
|
12
|
Zadow EK, Wundersitz DWT, Hughes DL, et al. Coronavirus (COVID-19), coagulation, and
exercise: interactions that may influence health outcomes. Semin Thromb Hemost 2020;46(7):807–814
|
|
13
|
Demers M, Wagner DD. NETosis: a new factor in tumor progression and cancer-associated
thrombosis. Semin Thromb Hemost 2014;40(3):277–283
|
|
14
|
Raskob GE, Angchaisuksiri P, Blanco AN, et al; ISTH Steering Committee for World Thrombosis
Day. Thrombosis: a major contributor to global disease burden. Semin Thromb Hemost
2014;40(7):724–735
|
|
15
|
Favaloro EJ. Clinical utility of the PFA-100. Semin Thromb Hemost 2008;34(8):709–733
|
|
16
|
Stufano F, Boscarino M, Bucciarelli P, et al. Evaluation of the utility of von Willebrand
factor propeptide in the differential diagnosis of von Willebrand disease and acquired
von Willebrand syndrome. Semin Thromb Hemost 2019;45(1):36–42
|
|
17
|
Favaloro EJ, Pasalic L, Curnow J. Type 2M and Type 2A von Willebrand disease: similar
but different. Semin Thromb Hemost 2016;42(5):483–497
|
|
18
|
Lim MS, Indran T, Cummins A, et al. Utility of a nurse-led pathway for patients with
acute venous thromboembolism discharged on rivaroxaban: a prospective cohort study.
Semin Thromb Hemost 2019;45(2):187–195
|
|
19
|
Mannucci PM, Mancuso ME, Santagostino E, Franchini M. Innovative pharmacological therapies
for the hemophilias not based on deficient factor replacement. Semin Thromb Hemost
2016;42(5):526–532
|
|
20
|
Wada H, Usui M, Sakuragawa N. Hemostatic abnormalities and liver diseases. Semin Thromb
Hemost 2008;34(8):772–778
|
a 2019–2020 inclusive. Ranking is according to download data provided by journal publisher,
and excludes non-qualifying material (e.g., Prefaces, Errata, Letter to the Editor,
Editorials, Commentaries, and previous award-winning articles).
Table 4
Most popular papers—“General” category[a]
|
Rank
|
Publication
|
|
1
|
Iba T, Levi M, Levy JH. Sepsis-induced coagulopathy and disseminated intravascular
coagulation. Semin Thromb Hemost 2020;46(1):89–95
|
|
2
|
Thomas J, Kostousov V, Teruya J. Bleeding and thrombotic complications in the use
of extracorporeal membrane oxygenation. Semin Thromb Hemost 2018;44(1):20–29
|
|
3
|
Laridan E, Martinod K, De Meyer SF. Neutrophil extracellular traps in arterial and
venous thrombosis. Semin Thromb Hemost 2019;45(1):86–93
|
|
4
|
Scharf RE. Drugs that affect platelet function. Semin Thromb Hemost 2012;38(8):865–883
|
|
5
|
Boccardo P, Remuzzi G, Galbusera M. Platelet dysfunction in renal failure. Semin Thromb
Hemost 2004;30(5):579–589
|
|
6
|
Maclachlan KH, Stevens HP, Tran HA, Chunilal SD. Weight-based enoxaparin for venous
thromboembolism in obesity gives similar anti-Xa levels to patients <100 kg, with
no increase in major bleeding. Semin Thromb Hemost 2019;45(1):94–99
|
|
7
|
Baskurt OK, Meiselman HJ. Blood rheology and hemodynamics. Semin Thromb Hemost 2003;29(5):435–450
|
|
8
|
Franchini M, Mannucci PM. The history of hemophilia. Semin Thromb Hemost 2014;40(5):571–576
|
|
9
|
Favaloro EJ, Kershaw G, Mohammed S, Lippi G. How to optimize activated partial thromboplastin
time (APTT) testing: solutions to establishing and verifying normal reference intervals
and assessing APTT reagents for sensitivity to heparin, lupus anticoagulant, and clotting
factors. Semin Thromb Hemost 2019;45(1):22–35
|
|
10
|
Marlar RA, Clement B, Gausman J. Activated partial thromboplastin time monitoring
of unfractionated heparin therapy: issues and recommendations. Semin Thromb Hemost
2017;43(3):253–260
|
|
11
|
Bolliger D, Tanaka KA. Point-of-care coagulation testing in cardiac surgery. Semin
Thromb Hemost 2017;43(4):386–396
|
|
12
|
Bikdeli B, Abou Ziki MD, Lip GYH. Pulmonary embolism and atrial fibrillation: two
sides of the same coin? A systematic review. Semin Thromb Hemost 2017;43(8):849–863
|
|
13
|
Mahajan A, Brunson A, White R, Wun T. The epidemiology of cancer-associated venous
thromboembolism: an update. Semin Thromb Hemost 2019;45(4):321–325
|
|
14
|
Van Cott EM, Roberts AJ, Dager WE. Laboratory monitoring of parenteral direct thrombin
inhibitors. Semin Thromb Hemost 2017;43(3):270–276
|
|
15
|
Davie EW, Kulman JD. An overview of the structure and function of thrombin. Semin
Thromb Hemost 2006;32(suppl 1):3–15
|
|
16
|
Reynen E, James P. Von Willebrand disease and pregnancy: a review of evidence and
expert opinion. Semin Thromb Hemost 2016;42(7):717–723
|
|
17
|
McEwen BJ. The influence of herbal medicine on platelet function and coagulation:
a narrative review. Semin Thromb Hemost 2015;41(3):300–314
|
|
18
|
Thachil J. The elusive diagnosis of disseminated intravascular coagulation: does a
diagnosis of DIC exist anymore? Semin Thromb Hemost 2019;45(1):100–107
|
|
19
|
Lippi G, Plebani M, Favaloro EJ. Interference in coagulation testing: focus on spurious
hemolysis, icterus, and lipemia. Semin Thromb Hemost 2013;39(3):258–266
|
|
20
|
Arachchillage DRJ, Makris M. Inherited thrombophilia and pregnancy complications:
should we test? Semin Thromb Hemost 2019;45(1):50–60
|
|
21
|
Lippi G, Gosselin R, Favaloro EJ. Current and emerging direct oral anticoagulants:
state-of-the-art. Semin Thromb Hemost 2019;45(5):490–501
|
|
22
|
Molhoek JE, de Groot PG, Urbanus RT. The lupus anticoagulant paradox. Semin Thromb
Hemost 2018;44(5):445–452
|
|
23
|
Anker-Møller T, Troldborg A, Sunde N, Hvas AM. Evidence for the use of tranexamic
acid in subarachnoid and subdural hemorrhage: a systematic review. Semin Thromb Hemost
2017;43(7):750–758
|
|
24
|
Arachchillage DR, Laffan M. Pathogenesis and management of thrombotic disease in myeloproliferative
neoplasms. Semin Thromb Hemost 2019;45(6):604–611
|
|
25
|
Grandone E, Ostuni A, Tiscia GL, Marongiu F, Barcellona D. Management of patients
taking oral anticoagulants who need urgent surgery for hip fracture. Semin Thromb
Hemost 2019;45(2):164–170
|
a 2019–2020 inclusive. Ranking is according to download data provided by journal publisher,
and excludes non-qualifying material (e.g., Prefaces, Errata, Letter to the Editor,
Editorials, Commentaries, and previous award-winning articles).
Accordingly, the 2021 Eberhard F. Mammen award winners for most popular article (2019/2020
inclusive) are mentioned below:
Open Access Category
-
Gosselin RC, Adcock D, Dorgalaleh A, Favaloro EJ, Lippi G, Pego JM, Regan I, Siguret
V. International Council for Standardization in Haematology Recommendations for hemostasis
critical values, tests, and reporting. Semin Thromb Hemost 2020;46(4):398–409.[2]
-
Gosselin RC, Marlar RA. Preanalytical Variables in Coagulation Testing: Setting the
Stage for Accurate Results. Semin Thromb Hemost 2019;45(5):433–448.[3]
General Category
-
Iba T, Levi M, Levy JH. Sepsis-Induced Coagulopathy and Disseminated Intravascular
Coagulation. Semin Thromb Hemost 2020;46(1):89–95.[22]
-
Thomas J, Kostousov V, Teruya J. Bleeding and Thrombotic Complications in the Use
of Extracorporeal Membrane Oxygenation. Semin Thromb Hemost 2018;44(1):20–29.[23]
I will note that although I was a coauthor of one of the award-winning articles, my
relative contribution was minor in comparison to the lead author, and I will of course
decline to receive any of the award prize.
As always, and irrespective of any personal involvement in the writing of papers that
are published in this journal, I always get considerable satisfaction in announcing
these awards. This year also saw that one lead author, Robert C. Gosselin, wins two
of the top prizes for separate papers published in separate years.[2]
[3] Indeed, one of these papers was published in 2020,[2] and so is especially deserving, given the later publication of the 2-year, 2019
and 2020, capture period. This paper was prepared on behalf of the International Council
for Standardization in Haematology (ICSH).[47] It was only at e-First publication stage at the time of writing the previous editorial
related to the 2020 Eberhard F. Mammen “Most Popular” articles award announcements.[48] Nevertheless, it rated high on the 2020 listing and I predicted it to be very difficult
to beat for the 2021 “Most Popular” award.[48] The 2021 winner proves my prediction to be correct, despite some later “competition”
by popular COVID-19-related papers.
As always, the listing also identified some older yet popular papers in [Tables 3] and [4] and thus indicates some topics of current interest that STH will likely revisit
in forthcoming years.
It is certainly always of interest to see what captures the attention of the STH readership.
Some topics and issues of STH, in particular, seem to catch a larger readership. This
was certainly true of COVID-19 papers. STH published an issue on COVID-19 in 2020[49] and plans at least one issue in 2021. Indeed, most of the papers that appeared in
the 2020 COVID-19 issue also appeared in the top 100 download list, as listed in [Table 5]. Notably, most of these papers were Commentaries, and thus do not qualify for the
award. However, there were a couple of reviews included in the issue, and these would
likely be qualifiers for the 2022 “Most Popular” award.
Table 5
COVID-19-related papers, also very popular[a]
|
Publication
|
Position in 2021 top 100 list
|
|
Favaloro EJ, Lippi G. Recommendations for minimal laboratory testing panels in patients
with COVID-19: potential for prognostic monitoring. Semin Thromb Hemost 2020;46(3):379–382
|
3
|
|
Thachil J, Srivastava A. SARS-2 coronavirus-associated hemostatic lung abnormality
in COVID-19: is it pulmonary thrombosis or pulmonary embolism? Semin Thromb Hemost
2020;46(7):777–780
|
4
|
|
Schulman S. Coronavirus disease 2019, prothrombotic factors, and venous thromboembolism.
Semin Thromb Hemost 2020;46(7):772–776
|
10
|
|
Kwaan HC. Coronavirus disease 2019: the role of the fibrinolytic system from transmission
to organ injury and sequelae. Semin Thromb Hemost 2020;46(7):841–844
|
17
|
|
Larsen JB, Pasalic L, Hvas AM. Platelets in coronavirus disease 2019. Semin Thromb
Hemost 2020;46(7):823–825
|
21
|
|
de Maat S, de Mast Q, Danser AHJ, van de Veerdonk FL, Maas C. Impaired breakdown of
bradykinin and its metabolites as a possible cause for pulmonary edema in COVID-19
infection. Semin Thromb Hemost 2020;46(7):835–837
|
26
|
|
Di Minno A, Ambrosino P, Calcaterra I, Di Minno MND. COVID-19 and venous thromboembolism:
a meta-analysis of literature studies. Semin Thromb Hemost 2020;46(7):763–771
|
29
|
|
Levi M, Thachil J. Coronavirus disease 2019 coagulopathy: disseminated intravascular
coagulation and thrombotic microangiopathy-either, neither, or both. Semin Thromb
Hemost 2020;46(7):781–784
|
30
|
|
Coppola A, Tagliaferri A, Rivolta GF, Quintavalle G, Franchini M. Confronting COVID-19:
issues in hemophilia and congenital bleeding disorders. Semin Thromb Hemost 2020;46(7):819–822
|
46
|
|
Lindholm PF, Ramsey G, Kwaan HC. Passive immunity for coronavirus disease 2019: a
commentary on therapeutic aspects including convalescent plasma. Semin Thromb Hemost
2020;46(7):796–803
|
50
|
|
Hashemi A, Madhavan MV, Bikdeli B. Pharmacotherapy for prevention and management of
thrombosis in COVID-19. Semin Thromb Hemost 2020;46(7):789–795
|
79
|
|
Dorgalaleh A, Dabbagh A, Tabibian S, et al. Patients with congenital bleeding disorders
appear to be less severely affected by SARS-CoV-2: is inherited hypocoagulability
overcoming acquired hypercoagulability of coronavirus disease 2019 (COVID-19)? Semin
Thromb Hemost 2020;46(7):853–855
|
94
|
Abbreviation: COVID-19, novel coronavirus disease 2019.
a 2019–2020 inclusive. Ranking is according to download data provided by journal publisher,
and includes nonqualifying material (e.g., Letters to the Editor and Commentaries)
for “Most Popular” awards. All COVID-19 related material provided as free to download
by Thieme.
The other top-ranking issues of STH this round, from the aspect of having three or
more papers appearing in the top 100 download list, and published in the past 5 years
were: “Acquired Platelet Dysfunction-Laboratory and Clinical Implications.” (2020),[50] “Innovations in Thrombosis and Hemostasis: A Glimpse Towards the Future of Diagnostic
Analyzers.” (2019),[51] “Recent Advances in Thrombosis and Hemostasis-Part IV.” (2019),[52] “Editorial Compilation VI” (2019),[53] “Hemostasis in Exercise and the Athlete.” (2018),[54] and “Editorial Compilation V” (2017).[55]
It can be noted here that the latest “‘nonthemed” issues (into which primarily go
the best of unsolicited manuscripts) were well represented as “leading” issues, according
to this marker of “popularity.” This would help to vindicate the decision to progress
such issues approximately every 8 months.
All authors of the award-winning articles were thrilled to hear that their papers
had won an Eberhard F. Mammen “Most Popular” award, and provided their own personal
responses to the news.
From Robert C. Gosselin ([Fig. 2]), “on behalf of my coauthors, it is truly an honor to be bestowed two Eberhard F.
Mammen “Most Popular” article awards. Dr Mammen had a particular fondness for teaching,
especially laboratory technologists, which has inspired so many including myself to
reach out and share our experiences. It is my belief that a significant feature for
these awards is the acknowledgement that our colleagues yearn for these manuscripts
that provide technical guidance, and thus we are immensely grateful to STH for their
willingness to provide such a platform for these articles related to laboratory practice.
I would also like to thank Siemens Healthcare Diagnostics for providing Dr. Marlar
([Fig. 3]) and myself the inspiration to write the preanalytical variable manuscript, as well
as the ICSH for providing support for the coagulation critical value manuscript.”
Fig. 2 Robert C. Gosselin.
Fig. 3 Richard A. Marlar.
Richard A. Marlar ([Fig. 4]) added, “I wish to thank the editors and staff of STH for awarding Bob Gosselin
and myself the honor of an Eberhard F. Mammen “Most Popular” article award for our
article on preanalytical variables. Dr. Mammen truly was gifted for teaching and mentoring.
I knew him throughout my career from his classroom teaching while in graduate school
at the start of my career to mentoring and helping me set my direction into coagulation
laboratory science. Finally, he continued to advise and mentor throughout my career
on many different topics. It is truly an honor for me to have worked and interacted
with him and his family. Thanks must be also extended to Siemens Healthcare Diagnostics
for providing the opportunity to write a review manuscript on preanalytical variables
in coagulation. And for the willingness of the editors of this journal to review and
then accept our manuscript. It is gratifying to know that our work was truly needed
and hopefully has helped make coagulation laboratories better.”
Fig. 4 From left: Jerrold H. Levy, Toshiaki Iba, Marcel Levi.
It was very pleasing to see (open disclosure here: my friend and sometimes collaborator)
Robert C. Gosselin win awards for these two reviews.[2]
[3] I recall the development of both these manuscripts, both appearing in separate issues
in which I and another friend and sometimes collaborator, Prof. Giuseppe Lippi, guest
edited.[56]
[57] Also of interest, Robert C. Gosselin was coauthor of a 2019 “Most Popular” award
winning paper.[58]
[59] Also of interest, especially as a connection to Dr. Mammen, is that Robert C. Gosselin
was a coauthor on one of Dr. Mammen's publications appearing in STH in 1998.[60]
From Toshiaki Iba ([Fig. 4]), speaking on behalf of all authors (also appearing in [Fig. 4]), “we are greatly honored to have received one of the Eberhard F. Mammen STH 2021
“Most Popular” article awards. Upon receiving the award, we must confess that the
concept of disseminated intravascular coagulation (DIC) has not yet been integrated
between the scientists and countries per se. DIC has perhaps become diffuse intercerebral confusion or disseminated intercontinental
chaos. My wonderful colleagues Profs. Jerrold H. Levy and Marcel Levi and I have been
worked on unifying the concept of sepsis-associated DIC and released the diagnostic
criteria for sepsis-induced coagulopathy (SIC) in 2017. Since then, we are continuously
working on expanding the “two-step approach (SIC to DIC)” to manage DIC in sepsis.
Our future target is establishing an effective strategy for DIC. We also wish to clarify
the difference and similarities between SIC and COVID-19-associated coagulopathy.
We are extremely happy that we could introduce this process in this prestigious journal.”
From Jun Teruya ([Fig. 5]), speaking also on behalf of his coauthors (also appearing in [Fig. 5]): “we were surprised, thrilled, and grateful to hear that our paper had won one
of the 2021 Eberhard F. Mammen “Most Popular” awards for the “General Category.” We
are pleased to know that our article entitled “Bleeding and Thrombotic Complications
in the Use of Extracorporeal Membrane Oxygenation (ECMO)” was widely read by people
who presumably manage patients on ECMO on a daily basis. Even with the advancement
of recent technology, we still struggle with bleeding and thrombosis during ECMO.
We hope that our article was helpful to guide management of patients on ECMO. On a
personal note, I was fortunate to attend Dr. Mammen's talk when he came to Tokyo,
Japan, in the late 1980's. I was a resident at that time, but his talk convinced me
to specialize in hemostasis as my career.”
Fig. 5 From left: James Thomas, Vadim Kostousov, extracorporeal membrane oxygenation (ECMO)
machine, Jun Teruya.
Also interesting is that several papers on the top listings were coauthored by previous
Young Investigator Award winners, for example, the paper by Laridan et al,[24] which just missed out on a “Most Popular” award, being third on the list in [Table 4]. Elodie Laridan was a 2017 “Young Investigator” award winner,[61] and this paper represents the contribution submitted as part of the award. This
also further helps to validate the “Young Investigator” awards process itself.
Also, perhaps notable is that several of the papers listed on the most popular tables
are original studies,[10]
[17]
[19]
[27] or what I call “hybrid papers” (representing some original data and a review of
the literature)."[12] Given the current restrictive Publication Policy for original studies published
in STH,[62] I find it interesting that four original studies published in 2019 appeared on the
top 100 listing. In brief, STH publishes a maximum of 10 to 12 original studies per
year, and these also require additional oversight with external to STH-board peer
review. Nonetheless, that 4 of 11 original studies published in 2019 appeared in the
top 100 seems to validate the Editorial Board's decision to continue to publish selected
unsolicited submissions of original studies. Of note, an original study also won one
of the 2020 “Most Popular” awards.[48]
[63]
I would, as always, like to thank not only all of the authors listed in [Tables 2]
[3]
[4]
[5], but also all the other contributing authors who didn’t manage to make these listings,
as well as all the many other guest editors of issues recently published in STH. I likewise look forward to seeing future listings, always a great pleasure and sometimes
a surprise.
